EHRA 2024: Late-Breaking Science Video Collection
Published: 22 April 2024
-
Views:
1267
-
Likes:
7
-
Views:
1267
-
Likes:
7
-
Up Next -
4m 3sPart 1 | Session 2 FIH Clinical Series of Conformable "Single Shot" PFA Catheter for PVI -
8m 5sPart 1 | Session 3 Risk of Stroke or Embolism and AF: ARTESiA Substudy -
2m 53sPart 1 | Session 4 Ablation Strategies for Repeat Procedures in Recurrent AF: ASTRO -
5m 26sPart 1 | Session 5 Non-Vitamin K Antagonist Oral Anticoagulant in AHRE Patients: NOAH -
6m 51sPart 1 | Session 6 Personalised PVI: The QDOT-by-LAWT Trial -
7m 10sPart 1 | Session 7 AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease
Overview
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
Part 1
Expert Interviews
Part 2
Highlights
About the episode
EHRA 24 - We are joined onsite by Dr Roland Tilz (University Heart Center, DE) to discuss the findings of the Style-AF study (NCT05563142).
This prospective, randomized, controlled study aims to compare the safety and efficacy of the Perclose ProStyle suture-medicated closure device to manual compression for the treatment of hemostasis after single-shot-device pulmonary vein isolation (PVI). 125 patients were enrolled in the trial, who were randomized in a 1:1 ratio to either recieve the ProStyle closure device, or manual compression with a figure-of-eight stitch. The primary outcome endpoint of the study were time to hemostasis, and the primary safety endpoint was the total number of major complications.
Findings of the study were positive, with the ProStyle device resulting in a significantly faster time to ambulation with no difference in terms of complication between both groups. In terms of secondary endpoints, time to discharge eligibility and hemostasis was significantly shorter in the vascular closure arm, and patient satisfaction found to be higher.
Interview Questions:
- What is the reasoning behind this study?
- Could you tell us a bit more about the ProStyle Closure Device?
- What was the study design and patient population?
- What were your key findings revealed at EHRA 24?
- What questions remain?
- What are your key take-home messages?
- What are the next steps?
Recorded on-site at EHRA in Berlin, 2024.
Faculty Biographies
Roland R Tilz
Prof Roland Tilz is the deputy director of the Medical Center II of the University Hospital in Lübeck and professor of the invasive electrophysiology at the University Lübeck. He is committed to training in the field of “Invasive electrophysiology and cardiac rhythm implants”. Prof Roland Tilz trained at the Addenbrooks Hospital in Cambridge (UK), Bedford Hospital (UK), Klinikum Bayreuth and at the Asklepios Klinik St. Georg in Hamburg.
Comments